Cyteir

Develops small molecules for the treatment of cancer and autoimmune diseases

placeCambridge, Massachusetts, United States calendar_todayFounded 2012 groups46 employees language cyteir.com

Registered entities

Investor mix

18 investors on record; lead investors include RA Capital Management, Venrock, Celgene, Novo Holdings; 1 has since exited.

Investor typeCountShare
Venture capital844%
Private equity16%
Other / undisclosed950%
Coming soon